<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418145</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 01-0781</org_study_id>
    <secondary_id>RG 3363A8</secondary_id>
    <nct_id>NCT00418145</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks</brief_title>
  <official_title>Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the relative efficacy of treating acute exacerbations of
      relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV)
      methylprednisolone. This is a randomized, blinded, multi-center study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous methylprednisolone has been the standard of care for treating acute MS flares.
      However, the IV administration is cumbersome, inconvenient and expensive. A true comparison
      of these different approaches has not been undertaken in rigorous fashion. Prior studies have
      demonstrated the safety of such high doses of oral steroid. For this proposal we employ
      equivalent oral dosing (1400 mg/day) and compare that to 1000 mg/day IV therapy in patients
      seen within seven days of an acute exacerbation of MS.

      In addition, there are 2 arms to this double-blind, placebo controlled, randomized trial. One
      arm has an active IV and an oral placebo while the second arm has an IV placebo and an active
      oral dose. Therefore, each subject will receive an active treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment - data was not analyzed for this study
  </why_stopped>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28.</measure>
    <time_frame>Day 28 and Day 90</time_frame>
    <description>There is no data analysis for this study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters of the Multiple Sclerosis Functional Composite Scale (MSFC) Between Oral and IV Steroid Therapy in Subjects With Relapsing Forms of MS.</measure>
    <time_frame>Day 28 and day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Relapse Over Time (up to One Year) When Subjects With Relapsing Forms of MS Are Administered One Course of Oral Methylprednisolone Compared to IV Administration.</measure>
    <time_frame>Day 28 and day 90 and day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement Using Targeted Neurological Deficits (TND).</measure>
    <time_frame>Day 28 and day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>megadose oral methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1400 mg qd/5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg/qd/5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megadose oral methylprednisolone</intervention_name>
    <description>1400 mg qd/5 days</description>
    <arm_group_label>megadose oral methylprednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV methylprednisolone</intervention_name>
    <description>1000 mg/qd/5 days</description>
    <arm_group_label>IV methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 50 years, inclusive.

          -  Acute symptomatic exacerbation of MS present for great than 24 hours and less than or
             equal to 7 days at entry with new or worsening symptoms, and with signs referable to
             the symptoms; in the absence of a fever or active infection.

          -  Diagnosis of a relapsing form of multiple sclerosis before randomization as determined
             by Poser or McDonald Criteria.

          -  Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.

          -  Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic
             neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or
             definitive focal sensory dysfunction.

          -  New objective clinical finding other than a sensory exacerbation, or bowel/bladder
             signs alone. Sensory deficits alone will not qualify except for optic neuritis.

          -  Subjects may continue on their current immunomodulating therapy (such as interferons
             or glatiramer acetate) throughout the course of the study. Women who become pregnant
             after the 5-day treatment of steroids should discontinue immunomodulatory treatment.

          -  Understand and sign written informed consent prior to any testing under this protocol,
             including screening tests and evaluations that are not considered part of the
             subject's routine care.

        Exclusion Criteria:

          -  Any patients treated with systemic corticosteroid use within one month of the index
             episode at screening.

          -  Prior use of immunosuppressive treatments within 90 days of index episode
             (mitoxantrone, azathioprine, IVIg) or plasmapheresis.

          -  Any patient who is pregnant or breastfeeding.

          -  Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed
             25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).

          -  Peripheral or cranial neuropathy as sole problem of acute episode.

          -  History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal
             disease; immune deficiency; or other medical conditions that would preclude
             corticosteroid therapy.

          -  Primary Progressive Multiple Sclerosis (PPMS).

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Lublin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jacobs Neurological Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital For Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Presbyterian Hospital-Cornell University New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont, Burlington</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>August 5, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Fred Lublin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Relapsing Forms of Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Study Participants</title>
          <description>Overall study participants. Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>16 participants were enrolled into the study. Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
      <group_list>
        <group group_id="B1">
          <title>Total Study Participants</title>
          <description>Overall study participants - Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>age 18-29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age 30-39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age 40-49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age 50+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28.</title>
        <description>There is no data analysis for this study</description>
        <time_frame>Day 28 and Day 90</time_frame>
        <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
        <group_list>
          <group group_id="O1">
            <title>Megadose Oral Methylprednisolone</title>
            <description>1400 mg qd/5 days
megadose oral methylprednisolone: 1400 mg qd/5 days</description>
          </group>
          <group group_id="O2">
            <title>IV Methylprednisolone</title>
            <description>1000 mg/qd/5 days
IV methylprednisolone: 1000 mg/qd/5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28.</title>
          <description>There is no data analysis for this study</description>
          <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Parameters of the Multiple Sclerosis Functional Composite Scale (MSFC) Between Oral and IV Steroid Therapy in Subjects With Relapsing Forms of MS.</title>
        <time_frame>Day 28 and day 90</time_frame>
        <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
        <group_list>
          <group group_id="O1">
            <title>Megadose Oral Methylprednisolone</title>
            <description>1400 mg qd/5 days
megadose oral methylprednisolone: 1400 mg qd/5 days</description>
          </group>
          <group group_id="O2">
            <title>IV Methylprednisolone</title>
            <description>1000 mg/qd/5 days
IV methylprednisolone: 1000 mg/qd/5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Parameters of the Multiple Sclerosis Functional Composite Scale (MSFC) Between Oral and IV Steroid Therapy in Subjects With Relapsing Forms of MS.</title>
          <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Relapse Over Time (up to One Year) When Subjects With Relapsing Forms of MS Are Administered One Course of Oral Methylprednisolone Compared to IV Administration.</title>
        <time_frame>Day 28 and day 90 and day 365</time_frame>
        <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
        <group_list>
          <group group_id="O1">
            <title>Megadose Oral Methylprednisolone</title>
            <description>1400 mg qd/5 days
megadose oral methylprednisolone: 1400 mg qd/5 days</description>
          </group>
          <group group_id="O2">
            <title>IV Methylprednisolone</title>
            <description>1000 mg/qd/5 days
IV methylprednisolone: 1000 mg/qd/5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Relapse Over Time (up to One Year) When Subjects With Relapsing Forms of MS Are Administered One Course of Oral Methylprednisolone Compared to IV Administration.</title>
          <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement Using Targeted Neurological Deficits (TND).</title>
        <time_frame>Day 28 and day 90</time_frame>
        <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
        <group_list>
          <group group_id="O1">
            <title>Megadose Oral Methylprednisolone</title>
            <description>1400 mg qd/5 days
megadose oral methylprednisolone: 1400 mg qd/5 days</description>
          </group>
          <group group_id="O2">
            <title>IV Methylprednisolone</title>
            <description>1000 mg/qd/5 days
IV methylprednisolone: 1000 mg/qd/5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement Using Targeted Neurological Deficits (TND).</title>
          <population>Data is also no longer accessible. Data was with biostatistician who no longer has data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Data is also no longer accessible. Data was with biostatistician who no longer has data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Megadose Oral Methylprednisolone</title>
          <description>1400 mg qd/5 days
megadose oral methylprednisolone: 1400 mg qd/5 days</description>
        </group>
        <group group_id="E2">
          <title>IV Methylprednisolone</title>
          <description>1000 mg/qd/5 days
IV methylprednisolone: 1000 mg/qd/5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated due to difficulties obtaining drug and matching placebo and the inability to meet recruitment. There was no data analysis done for this trial due to low enrollment and data will not be meaningful.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Fred Lublin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6854</phone>
      <email>fred.lublin@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

